Xbrane today provided an update on the expected timeline for the resubmission of the BLA for its ranibizumab biosimilar, indicating a planned March resubmission. This would imply an expected BsUFA date in September, representing slightly shorter lead time than we had previously anticipated.
LÄS MER
